Free Trial
→ Trump’s issues shocking Executive Order on U.S. Dollar (From Banyan Hill Publishing) (Ad)tc pixel
NYSEAMERICAN:CATX

Perspective Therapeutics Q3 2026 Earnings Date & Estimates

Perspective Therapeutics logo
$1.08 -0.07 (-5.65%)
As of 11:19 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Perspective Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for November 11, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Perspective Therapeutics in Q3 2026

Perspective Therapeutics is expected to post earnings of -$0.24 per share on revenue of $56 thousand. In the same quarter a year earlier Perspective Therapeutics reported -$0.35 per share on revenue of $209 thousand. Perspective Therapeutics last reported on August 10, 2026, posting -$0.22 per share and beating the -$0.2511 consensus estimate. Perspective Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.24
Expected Revenue
$56 thousand
Prior-Year EPS
-$0.35
Prior-Year Revenue
$209 thousand
Expected Revenue Growth
-73.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.22 (Beat by +$0.0311)
Last Quarter Revenue
$81 thousand
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Perspective Therapeutics Q3 2026 Earnings FAQ

Perspective Therapeutics (NYSEAMERICAN:CATX) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Perspective Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Perspective Therapeutics to post earnings of -$0.24 per share for Q3 2026.

The consensus revenue estimate for Perspective Therapeutics is $56 thousand for Q3 2026.

Perspective Therapeutics Earnings Headlines

Perspective Therapeutics consensus price target decreased by 13.02% to $10.78
 |  msn.comhttps://www.msn.com/en-us/news/other/perspective-therapeutics-consensus-price-target-decreased-by-1302-to-1078/ar-AA2gy2x1
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Has Consensus Target Price of $10.50 According to Analysts
November 1 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31171040
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
November 2 at 1:00 AM  |  Decentralized Masters (Ad)
Perspective Therapeutics (CATX) Stock Sees Fair Value Moves Lower As Analysts Weigh Lead 212 Risks
October 31 at 12:36 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/perspective-therapeutics-catx-stock-sees-021235322.html
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC)
October 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8470280/analysts-are-bullish-on-top-healthcare-stocks-perspective-therapeutics-catx-oric-pharmaceuticals-oric/
RBC Capital downgrades Perspective Therapeutics to sector perform from outperform
October 26, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/rbc-capital-downgrades-perspective-therapeutics-to-sector-perform-from-outperform/ar-AA2g7SKD
See More Perspective Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Perspective Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perspective Therapeutics and other key companies, straight to your email.

About Perspective Therapeutics

Perspective Therapeutics (NYSEAMERICAN:CATX) is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors. Perspective has also developed PSMA-targeted programs intended to address prostate cancer and other tumors that express prostate-specific membrane antigen. Its activities include radiopharmaceutical research, clinical development, and the development of manufacturing and delivery capabilities to support these therapies.

Perspective Therapeutics is headquartered in Seattle, Washington, and has focused its operations on advancing targeted alpha therapies through clinical testing. The company is led by Marc H. Hedrick, M.D., who serves as president and chief executive officer. Its investigational products have not been established as safe or effective for commercial use unless approved by applicable regulatory authorities.

View Perspective Therapeutics Profile
Earnings Tools